Successful treatment of pediatric post-liver transplant Kaposi's sarcoma with paclitaxel
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.24953/turkjped.2020.05.020
dc.identifier.other
dc.description.volume
62
dc.description.issue
5
SEP-OCT
SEP-OCT
Publisher
TURKISH J PEDIATRICS
DOI
10.24953/turkjped.2020.05.020
Abstract
Background. Kaposi's sarcoma (KS) is a complication of immunosuppressive therapy for transplant recipients. Unlike adult recipients, KS in pediatric organ transplantation is quite rare. Treatment is usually withdrawal of immunosuppression
non-responders often receive chemotherapy. Case. We have reported a child with post-liver transplant visceral KS which has progressed despite withdrawal of immunosuppressive therapy, who has been treated with Paclitaxel for three weeks. KS has regressed completely after four cycles of Paclitaxel. Conclusion. Paclitaxel should be considered as an effective first line treatment option for patients with post-transplant KS.
non-responders often receive chemotherapy. Case. We have reported a child with post-liver transplant visceral KS which has progressed despite withdrawal of immunosuppressive therapy, who has been treated with Paclitaxel for three weeks. KS has regressed completely after four cycles of Paclitaxel. Conclusion. Paclitaxel should be considered as an effective first line treatment option for patients with post-transplant KS.